
Ab Initio Pharma, a formulation and manufacturing company, established as a spinoff by the University of Sydney in partnership with Sydney Local Health Distinct and the peak industry body, ACRS will provide innovators with a flexible platform to rapidly translate bench-top discoveries to clinical trial products and fully-fledged commercial pharmaceuticals. Importantly, Ab Initio will have R&D facilities and be able to offer its partners formulation services to develop products suitable for clinical trials.
Annual Revenue$10M to $25M
Estimated OwnershipPrivateBuilt from contact records that share this company: name, job title, job level, job function and person location.
Turn cold outreach into meaningful business conversations.
Rated and recommended by professionals who expect more
Matching runs on fields we already have: industry, employee range, HQ location, ownership type, funding rounds, specialities. Results come live from the ReachStream directory.